Vikki Tang
About
Vikki Tang is a scholar working on Oncology, Hepatology and Surgery.
According to data from OpenAlex, Vikki Tang has authored 20 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Hepatology and 6 papers in Surgery. Recurrent topics in Vikki Tang's work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Vikki Tang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Colorectal Cancer Treatments and Studies (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Vikki Tang collaborates with scholars based in China, Hong Kong and Canada. Vikki Tang's co-authors include Thomas Yau, Ronnie T. P. Poon, Tzy‐Jyun Yao, Chung‐Mau Lo, Roland Leung, Joanne Wing Yan Chiu, Wong Hoi She, Ka Wing, Jeffrey Sum Lung Wong and Tan To Cheung and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Annals of Surgical Oncology.
In The Last Decade
Vikki Tang
18 papers receiving 707 citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Vikki Tang China | 8 | 564 | 311 | 197 | 183 | 109 | 20 | 711 | ||
| Emmanuelle Coderc France | 9 | 710 1.3× | 499 1.6× | 187 0.9× | 105 0.6× | 51 0.5× | 15 | 820 | ||
| Yong Le China | 10 | 464 0.8× | 136 0.4× | 189 1.0× | 131 0.7× | 128 1.2× | 11 | 652 | ||
| Osakuni Morimoto Japan | 11 | 484 0.9× | 288 0.9× | 203 1.0× | 190 1.0× | 161 1.5× | 44 | 738 | ||
| Naoya Kanogawa Japan | 14 | 527 0.9× | 295 0.9× | 151 0.8× | 83 0.5× | 97 0.9× | 43 | 695 | ||
| A Nonomura Japan | 9 | 284 0.5× | 176 0.6× | 223 1.1× | 234 1.3× | 109 1.0× | 18 | 637 | ||
| Hirokazu Chishina Japan | 18 | 900 1.6× | 378 1.2× | 199 1.0× | 225 1.2× | 163 1.5× | 44 | 1.1k | ||
| Diyang Xie China | 8 | 436 0.8× | 215 0.7× | 149 0.8× | 150 0.8× | 150 1.4× | 10 | 632 | ||
| Poh Seng Tan Singapore | 12 | 259 0.5× | 166 0.5× | 128 0.6× | 67 0.4× | 124 1.1× | 26 | 541 | ||
| Jong Young Choi South Korea | 18 | 899 1.6× | 397 1.3× | 315 1.6× | 171 0.9× | 178 1.6× | 33 | 1.1k | ||
| Kensaku Sanefuji Japan | 15 | 380 0.7× | 171 0.5× | 334 1.7× | 147 0.8× | 79 0.7× | 29 | 611 |
Countries citing papers authored by Vikki Tang
Since
Specialization
Citations
This map shows the geographic impact of Vikki Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikki Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikki Tang more than expected).
Fields of papers citing papers by Vikki Tang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Vikki Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikki Tang. The network helps show where Vikki Tang may publish in the future.
Co-authorship network of co-authors of Vikki Tang
This figure shows the co-authorship network connecting the top 25 collaborators of Vikki Tang. A scholar is included among the top collaborators of Vikki Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikki Tang. Vikki Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lam, Ka-On, et al.. (2025). Trifluridine/Tipiracil (FTD/TPI) in Metastatic Colorectal Cancer in Hong Kong: A Territory-Wide Cohort Study. Advances in Therapy. 42(2). 1222–1236.
2.
Leung, Roland, Jeffrey Sum Lung Wong, Vikki Tang, et al.. (2024). A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease progression on standard tyrosine kinase inhibitors (TKIs).. Journal of Clinical Oncology. 42(23_suppl). 198–198.
3.
Chiu, Joanne Wing Yan, Gerry Gin Wai Kwok, Vikki Tang, et al.. (2021). The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. Advances in Therapy. 38(7). 3900–3910.
4.
Lui, David Tak Wai, Chi‐Ho Lee, Vikki Tang, et al.. (2021). Thyroid Immune-Related Adverse Events in Patients with Cancer Treated with anti-PD1/anti-CTLA4 Immune Checkpoint Inhibitor Combination: Clinical Course and Outcomes. Endocrine Practice. 27(9). 886–893.
5.
Wong, Jeffrey Sum Lung, Vikki Tang, Thomas W. T. Leung, et al.. (2021). The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study. Cancers. 13(9). 2002–2002.
6.
Wong, Jeffrey Sum Lung, Vikki Tang, Bryan Li, et al.. (2021). Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.. Journal of Clinical Oncology. 39(3_suppl). 330–330.
7.
Wong, Jeffrey Sum Lung, Vikki Tang, Bryan Li, et al.. (2021). Nivolumab/pembrolizumab in Child-Pugh grade B/C patients with advanced HCC.. Journal of Clinical Oncology. 39(15_suppl). e16184–e16184.
8.
Leung, Thomas W. T., Vikki Tang, Bryan Li, et al.. (2021). The use of cabozantinib in advanced hepatocellular carcinoma (HCC): Hong Kong multi-center experience.. Journal of Clinical Oncology. 39(3_suppl). 316–316.
9.
Wong, Jeffrey Sum Lung, Gerry Gin Wai Kwok, Vikki Tang, et al.. (2021). Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 9(2). e001945–e001945.
10.
Yau, Thomas, Joycelyn Jie Xin Lee, Jeffrey Sum Lung Wong, et al.. (2021). Outcomes of tyrosine kinase inhibitors after immunotherapy in advanced hepatocellular carcinoma: A multi-center study.. Journal of Clinical Oncology. 39(15_suppl). e16181–e16181.
11.
Wong, Jeffrey Sum Lung, Vikki Tang, Thomas W. T. Leung, et al.. (2021). Cabozantinib in advanced HCC patients previously treated with immune checkpoint inhibitors: A territory-wide cohort study.. Journal of Clinical Oncology. 39(15_suppl). e16179–e16179.
12.
Chiu, Joanne, Roland Leung, Vikki Tang, et al.. (2019). Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy. Postgraduate Medical Journal. 95(1121). 155–161.
13.
Yau, Thomas Cheung, Vikki Tang, Roland Leung, et al.. (2019). Randomized phase II trial of sorafenib, capecitabine and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 37(4_suppl). 365–365.
14.
Tang, Vikki, Roland Leung, Ann‐Shing Lee, et al.. (2019). Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 37(15_suppl). e15630–e15630.
15.
Yau, Thomas Cheung, Vikki Tang, Joanne Chiu, et al.. (2019). Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.. Journal of Clinical Oncology. 37(4_suppl). 361–361.
16.
Yau, Thomas, et al.. (2014). Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma. Gastroenterology. 146(7). 1691–1700.e3.
17.
Yau, Thomas Cheung, Vikki Tang, Joanne Chiu, Hilda Wong, & Roland Leung. (2014). Efficacy and saftey of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment-refractory metastatic colorectal cancer: A prospective, open-label, phase II study.. Journal of Clinical Oncology. 32(15_suppl). e14511–e14511.
18.
Chiu, Joanne Wing Yan, Vikki Tang, Roland Leung, et al.. (2013). Efficacy and Tolerability of Adjuvant Oral Capecitabine plus Intravenous Oxaliplatin (XELOX) in Asian Patients with Colorectal Cancer: 4-Year Analysis. Asian Pacific Journal of Cancer Prevention. 14(11). 6585–6590.
19.
Wong, Hilda, Kai Pun Wong, Thomas Yau, et al.. (2012). Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?. Annals of Surgical Oncology. 19(11). 3479–3485.
20.
Tang, Vikki, et al.. (2006). A framework for reducing instruction scheduling overhead in dynamic compilers. 5–5.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Emmanuelle Coderc Breakdown of academic impact, for papers by Yong Le Breakdown of academic impact, for papers by Osakuni Morimoto Breakdown of academic impact, for papers by Naoya Kanogawa Breakdown of academic impact, for papers by A Nonomura Breakdown of academic impact, for papers by Hirokazu Chishina Breakdown of academic impact, for papers by Diyang Xie Breakdown of academic impact, for papers by Poh Seng Tan Breakdown of academic impact, for papers by Jong Young Choi Breakdown of academic impact, for papers by Kensaku Sanefuji